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Samantha C. Salvage  5, Andrew A. Grace4, Christopher L.-H. Huang1,4 & Kamalan 
Jeevaratnam  2,3
Long QT Syndrome 3 (LQTS3) arises from gain-of-function Nav1.5 mutations, prolonging action 
potential repolarisation and electrocardiographic (ECG) QT interval, associated with increased age-
dependent risk for major arrhythmic events, and paradoxical responses to β-adrenergic agents. 
We investigated for independent and interacting effects of age and Scn5a+/ΔKPQ genotype in 
anaesthetised mice modelling LQTS3 on ECG phenotypes before and following β-agonist challenge, and 
upon fibrotic change. Prolonged ventricular recovery was independently associated with Scn5a+/ΔKPQ 
and age. Ventricular activation was prolonged in old Scn5a+/ΔKPQ mice (p = 0.03). We associated 
Scn5a+/ΔKPQ with increased atrial and ventricular fibrosis (both: p < 0.001). Ventricles also showed 
increased fibrosis with age (p < 0.001). Age and Scn5a+/ΔKPQ interacted in increasing incidences of 
repolarisation alternans (p = 0.02). Dobutamine increased ventricular rate (p < 0.001) and reduced both 
atrioventricular conduction (PR segment-p = 0.02; PR interval-p = 0.02) and incidences of repolarisation 
alternans (p < 0.001) in all mice. However, in Scn5a+/ΔKPQ mice, dobutamine delayed the changes 
in ventricular repolarisation following corresponding increases in ventricular rate. The present findings 
implicate interactions between age and Scn5a+/ΔKPQ in prolonging ventricular activation, correlating 
them with fibrotic change for the first time, adding activation abnormalities to established recovery 
abnormalities in LQTS3. These findings, together with dynamic electrophysiological responses to 
β-adrenergic challenge, have therapeutic implications for ageing LQTS patients.
Long QT Syndrome (LQTS) is characterised by prolonged electrocardiographic (ECG) QT intervals reflect-
ing increased ventricular action potential durations (APD) and is associated with increased incidences of 
arrhythmogenesis. The long QT syndrome 3 (LQTS3) variant specifically arises from gain-of-function muta-
tions in the inactivation domain of the SCN5A gene that encodes the cardiac Na+ channel, Nav1.51–3. These 
gain-of-function mutations result in recovery abnormalities attributable to increased late Na+ current (INa-L) 
known to enhance both triggers and substrates for arrhythmogenesis. Arrhythmic triggering arises from an occur-
rence of afterdepolarisation events during or immediately following an AP. Arrhythmic substrate arises from 
re-entrant processes re-exciting recovered regions resulting from the increased INa-L4.
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The aim of the present study to investigate the effects of age and adrenergic challenge on the LQTS3 pheno-
type was prompted by previous clinical and experimental work. Firstly, there is continued discussion concerning 
effects of effects of ageing in LQTS5 wherein human studies report reduced ages of onset (~50 ± 14 years) for atrial 
fibrillation (AF)6. More specifically in LQTS3, (a) LQTS3 genotypes were powerful predictors of fatal or near-fatal 
events after age 40, even compared to LQTS2 and LQTS1 genotypes, with similar risks associated with each LQTS 
genotype when excluding patients treated with β-blockers from the analysis7. (b) The specific association of LQTS 
arrhythmias occurring after 40 years of age with LQTS3 phenotypes8. (c) Complementary experimental studies 
showing increased arrhymogenicity with age in murine models of LQTS39.
Secondly, there are particular clinical paradoxical adrenergic effects in LQTS3. On the one hand, exercise 
and fright precipitate acute accentuations of QT interval prolongation, T-wave alternans and torsade de pointes 
accounting for 32% of fatal cardiac events in LQTS310, 11. Adrenergic provocation similarly provokes ECG T wave 
lability associated with cardiac arrest or syncope in some LQTS3 patients12. β blockade reduces risks of cardiac 
events specifically in female LQTS3 patients, although the effect in males is yet to be determined due to insuffi-
cient data13. On the other hand, in contrast to LQTS1 or LQTS2 patients, 39% of LQTS3 fatalities occur at rest 
or during sleep, when adrenergic tone is expected to be low and cholinergic activity is expected to be high11,14. 
A further clinical study associates higher incidences of cardiac events with both the LQTS3 and LQTS2 geno-
type amongst a cohort of LQTS patients treated with β blockers15. Similarly, contrasts between adrenergic effects 
have also been shown in experimental studies. Thus, β-adrenergic stimulation was variously pro-arrhythmic16, 
anti-arrhythmic17, 18 or without effect in LQTS3 models19. Furthermore, β -blockade was also shown to reduce 
arrhythmogenicity16, 20 and triggering events20. Yet other studies showed β -blockade accentuated reentrant sub-
strate19 and exacerbated transmural gradients of repolarisation with potential pro-arrhythmic effects20.
The present ECG and histological experiments explored the physiological basis for the above effects for the 
first time, using the Scn5a+/ΔKPQ murine model for LQTS3. This model carries a deletion of three conserved 
amino acids, Lys 1505, Pro 1506 and Gln 1507, in the Nav1.5 III–IV linker responsible for fast inactivation, 
known to correspond to a particularly severe clinical LQTS3 phenotype21, 22. Previous studies reported that the 
Scn5a+/ΔKPQ murine model recapitulated many clinical features of LQTS3, including its ECG abnormalities 
and arrhythmic tendency18, 19, 23. Previous work had demonstrated the mechanistic basis of possible arrhythmic 
phenotypes in studies demonstrating Na+ current abnormalities19, triggering events20, 24 and arrhythmic sub-
strate20, 25. The present work uses electrocardiographic and histological studies to examine for independent and 
interacting effects of ageing and Scn5a+/ΔKPQ genotype on arrhythmic phenotype and electrophysiological 
properties, before and following β1-adrenergic challenge, and the contribution of fibrotic change to these effects, 
in intact animals for first time.
Materials and Methods
Animals. A total of 12 wild-type (WT) and 13 Scn5a+/ΔKPQ S129sv mice were studied. They were housed in 
an animal facility maintained at 21 °C with 12 h light/dark cycles, fed sterile chow (RM3 Maintenance Diet; SDS, 
Witham, Essex, UK) and had free access to water. All experimental protocols were approved under the UK Home 
Office regulations (Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012) following ethical 
review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB) and conducted under 
a designated project license. The experiments also conformed to the Guide for the Care and Use of Laboratory 
Animals, U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996). The WT and Scn5a+/
ΔKPQ mice were each further divided into young (3 ± 1 month) and old (12 ± 1 month) groups.
Electrocardiographic analysis. For the electrocardiographic (ECG) study, the mouse groups consisted 
of young WT (n = 7), old WT (n = 5), young Scn5a+/ΔKPQ (n = 7) and old Scn5a+/ΔKPQ mice (n = 6). The 
ECG recordings followed a previously published approach26. To anaesthetise each mouse, avertin (2,2,2 trimethy-
lethanol, Sigma-Aldrich, Poole UK) was administered into the intra-peritoneal space before the ECG recordings 
were made. Avertin is known to have fewer cardiovascular and electrophysiological conduction effects than other 
anaesthetic agents, such as isoflurane and xylazine-ketamine27. For example, previous work indicated that keta-
mine provides reliable relaxation, sedation, and analgesia in mice but exerts bradycardic effects28. All measure-
ments were consistently performed after a 5-min period following establishment of anaesthesia and the recording 
setup in an attempt to allow autonomic levels to stabilise. The mice were left undisturbed in a dark box until the 
sedation took effect, weighed, and then placed in a supine position on a heated platform to maintain a 37 °C 
body temperature. Four 2-mm diameter electrodes (MLA1204; AD Instruments, Colorado Springs, CO, USA) 
were placed in the limbs and connected to a 4-channel NL844 pre-amplifier. The outputs were then led through 
4-channel NL820 isolator and NL135 low-pass filter units (set at a 1.0-kHz cut-off and with a 50-Hz notch) within 
a NL900D chassis and power supply (Neurolog-Digitimer, Hertfordshire, UK). The signal was sampled at 5 kHz 
and analogue-to-digital conversion employed a CED 1401c interface (Cambridge Electronic Design, Cambridge, 
UK). This then conveyed Lead II ECG traces to a computer for display and recording using Spike II software 
(Cambridge Electronic Design).
Baseline ECGs were recorded for 10- to 15-min, including a 5-min stabilisation period. Dobutamine hydro-
chloride (0.3 mg/kg: Sigma Aldrich, Poole UK) was then injected intraperitoneally. The ECG recordings con-
tinued for at least another 10-min after an observable effect on the ECG trace. Baseline stability in the ECG 
recordings was optimised by securing the limbs of the mice with adhesive tape to minimize movement artefacts 
and by performing experiments within a grounded Faraday cage to reduce electrical noise. The ECG record anal-
ysis also employed Spike II software and no digital filters were applied during the analysis. The ECG deflections 
ended with a “D peak” (Fig. 1a), which in some records could be preceded by an additional “C’ peak” (Fig. 1b) 
before final return of the trace to the isoelectric baseline. All the remaining peaks and troughs were consistent in 
their occurrence through all the experimental groups that were studied. Thus, there was an internally consistent 
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general ECG waveform, meaning that no traces were excluded. This allowed the application of cursors at the 
peaks and troughs of the trace as shown in the representative example in Fig. 2a. Only Lead II ECG traces were 
analysed. Lead I traces were used as references to guide application of cursors. The cursors indicate key reference 
features in the observed ECGs and were used to subsequently measure interval durations (Fig. 2b).
This analysis yielded the following ECG intervals which provide indications of different aspects of electro-
physiological function: RR interval (the ventricular rate reflecting sino-atrial node pacemaker function); P wave 
duration (atrial conduction time); PR segment duration (atrioventricular (AV) node conduction time); PR inter-
val (summed atrial and AV node conduction times); QS interval (ventricular activation time); SC and SD inter-
vals (indicators of ventricular recovery time); QC and QD intervals (indicators of the total duration of ventricular 
excitation). Earlier studies comparing recovery intervals at different heart rates used Bazett’s formula29 with an 
adjustment for mice: (QT/√(RR/100)30. However, the intervals analysed in the present study used uncorrected 
values. Thus recent reports pointed out that the modified Bazett’s formula can underestimate the QT interval and 
introduce systematic measurement errors in murine hearts, particularly for recovery diseases such as LQTS31–33
The data from the cursor time points was then imported into and analysed with custom-written software 
in the open-source R programming language (R Core Team, 2015). This was used to calculate the mean and 
standard errors of the desired ECG interval durations and to quantify the presence of Cpeak alternans. Analysis 
was performed on 300-sec of ECG data immediately prior to administration of dobutamine and 300-sec 
post-dobutamine period after having an observable effect. This quantitative analysis was only applied to parts of 
the trace showing a steady-state ventricular rate.
Histological analysis. The quantification of cardiac fibrosis followed methods used in previous studies in 
the Scn5a+/− mouse model and therefore permitted the present results to be compared with the previous obser-
vations34. The mice were killed by cervical dislocation and the hearts dissected out. Custom made Krebs buffer 
(containing, in mM, NaCl 119, NaHCO3 25, KCl 4, KH2PO4 1.2, MgCl2 1, CaCl2 1.8, glucose 10 and Na-pyruvate 
2, pH 7.4, 95% O2/5% CO2; British Oxygen Company, Manchester, UK) was used to flush the isolated hearts, 
which were then perfused with 4% buffered formalin for 5-min before being kept in formalin overnight. 
Following this fixation process, gross transverse sections were taken. This was followed by routine tissue pro-
cessing and paraffin embedding. The 7 μm thick sections were then stained using a Sirius red protocol, involving 
a series of immersions: xylene for 2-min; new batch of xylene for 2-min; 95%, 70% and 50% ethanol for 2-min 
each; Weigerts Haemotoxylin for 8-min; running water for 10-min; picro-sirius red solution for 1 hour; acidified 
water for 16 dips; 3 changes of 100% ethanol for 1-min each and xylene for 3 dips. The slides were then mounted 
and subsequently viewed, magnified, and digitally acquired using the Nano Zoomer 2.0 Digital Pathology system 
(Hamamatsu, Hertfordshire, UK).
Following magnification, a custom-made 17 cm × 30 cm morphometric grid, consisting of square boxes of 
dimension 1 cm × 1 cm, corresponding to an approximate 0.2 mm × 0.2 mm area of tissue, was then superim-
posed on each photomicrograph. If a square occupied either completely or partially by cardiac tissue showed the 
presence of fibrosis, it was counted and then the number of these squares was then expressed as a percentage of 
total cardiac tissue area for each heart. This analysis was carried out blindly by two investigators independently 
Figure 1. Representative peaks in the ECG records All peaks shown here, apart from C’peak, marked in red, were 
consistent across all the ECG records. C’peak was absent in some ECG records (a) but present in others (b). The 
cursors were then applied accordingly to encompass this difference, by including a QD duration, while allowing 
the same intervals to be analysed across all records.
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Figure 2. Schematic representation of the ECG analysis method (a) This representative lead II ECG trace 
obtained from an avertin anaesthetized mouse illustrates the cursors (dashed vertical lines) that were applied 
using Spike II software (Cambridge Electronic Design). Bipolar recordings were obtained with the negative 
electrode placed on the right forelimb and the positive electrode placed on the left hindlimb. The cursors 
indicate key reference features in the observed ECGs. Those marked in bold type were the key parameters 
sought in the automated analysis. Those marked in standard type indicate consistent features in the ECG traces 
that were used in the signal analysis programme to determine those key parameters. (b) This same example lead 
II ECG trace now has the intervals sought in the automated analysis programme superimposed. The key below 
the trace shows the physiological relevance of each of those ECG intervals. This analysis yielded the following 
ECG intervals which provide indications of different aspects of electrophysiological function: RR interval (the 
ventricular rate reflecting sino-atrial node pacemaker function); P wave duration (atrial conduction time); PR 
segment duration (atrioventricular (AV) node conduction time); PR interval (combined atrial and AV node 
conduction times); QS interval (ventricular activation time); SC and SD intervals (indicators of ventricular 
recovery time); QC and QD intervals (indicators of the total duration of ventricular excitation).
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and then their results were compared for consistency by applying an inter-class correlation coefficient analysis 
(ICC) to identify if both assessors were in agreement with what counted as fibrotic change. ICC can be interpreted 
as follows: 0–0.2 indicates poor agreement: 0.3–0.4 indicates fair agreement; 0.5–0.6 indicates moderate agree-
ment; 0.7–0.8 indicates strong agreement; and >0.8 indicates almost perfect agreement.
Statistical analysis. Statistical analyses used Stata SE14 (StataCorp, TX, USA). Each ECG feature or his-
tological parameter was analysed as a separate outcome using regression analysis. We adopted numbers of rep-
licates, n, for each experimental group, that were sufficient for this multivariable regression analysis. Although 
there are 3 variables (age, genotype and dobutamine challenge), our study involved paired comparisons and was 
confined to exploring two (and not three) way interactions between variables. We then emphasised only clear and 
significant associations, reporting conservatively on associations that were narrowly significant, and indicated 
instances where there was insufficient evidence to support an interaction, rather than inferring its absence. The 
choice of regression model was determined by the distribution of the parameter under analysis. Thus, the ECG 
intervals were analysed with multilevel linear regression. Histology results were analysed with a linear regression. 
The Cpeak alternans parameters included the number of incidences of an alternans episode and the total number of 
beats involving alternans. Both were analysed with a multilevel negative binomial regression. QC lag and QD lag 
were dichotomised into an absence or presence of such lag and analysed with a logistic regression.
To analyse the association between ECG features with dobutamine treatment, age and genotype, regression 
analyses were conducted in two parts. First a univariable regression analysis was performed to select possible risk 
factors and confounders. Variables with p < 0.20 were selected for the multivariable analyses. The multivariable 
regression analysis was performed using backwards elimination. All variables with univariable p < 0.20 were 
included in the first model and variables with p-value > 0.05 were eliminated from the model. To control for con-
founding, variables were eliminated one by one from the model. If the coefficients from the remaining variables 
were changed by >25%, the eliminated variable was then retained in the model as a confounder. Interactions 
were tested which were thought to be of biological interest. The following interactions were tested: age × geno-
type, age × treatment and genotype × treatment. Where appropriate, specifically when mice were treated with 
dobutamine, multilevel analyses were performed to adjust for multiple measurements per mouse.
Positive regression coefficients reflected an increase of the outcome with the named category in comparison 
with the reference category. Negative coefficients indicated a decrease in the outcome for the named category 
in comparison to the reference category. The reference categories were pre-dobutamine challenge for treatment, 
young for age and WT for genotype. A significant interaction means that the risk factor effects are not independ-
ent, but are different for various categories. Interpretation of this statistical analysis considered the following lim-
itations. First, a three-way interaction between age, genotype and treatment was not possible due to the available 
sample size. Secondly, the available sample size and the multiple parameters tested within these needed to con-
sider effects of multiple testing: the larger the numbers of parameters tested, the more likely any given parameter 
would appear to have an association with at least one category.
Results
Qualitative assessment of ECG records. Figure 3 shows examples of different types of ECG lead II 
waveforms observed in the avertin-anaesthetised mice. The predominant ECG waveform pattern across all 
groups, whether pre-or post-dobutamine challenge, was one of normal sinus rhythm (Fig. 3a). However, two 
old Scn5a+/ΔKPQ mice showed arrhythmic episodes post-dobutamine challenge. These patterns were not seen 
in young Scn5a+/ΔKPQ, consistent with possible influences of age on arrhythmic tendency. Thus, both of these 
old Scn5a+/ΔKPQ mice showed episodes of isorhythmic AV dissociation (Fig. 3b). During such episodes, the 
P wave morphology appeared identical to that seen during the previous periods of sinus rhythm and the corre-
sponding mean P–P interval was 178 ms. QRS morphology also appeared unchanged from the earlier periods 
Figure 3. Representative lead II ECG traces following qualitative analysis (a) This trace shows a normal sinus 
rhythm that was seen throughout the whole recordings, pre- and post-dobutamine challenge, in all young WT 
(n = 7), all old WT (n = 5) and all young Scn5a+/ΔKPQ (n = 7) but in 4 out of 6 of the old Scn5a+/ΔKPQ. (b) 
This trace shows isorhythmic AV dissociation that was observed in 2 out of 6 old Scn5a+/ΔKPQ mice post-
dobutamine. The arrows are pointing to the P waves, of which there is a noticeable absence in the middle part of 
the trace.
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of the recording and the R–R interval measured 172 ms. However, the PR interval progressively shortened with 
the P wave eventually merging with the QRS complex, culminating in its disappearance. The arrows in Fig. 3b 
indicate successive P waves immediately preceding the first five QRS complexes illustrated in the trace, and their 
disappearance in the next electrocardiographic complex, followed by their return. This return was associated with 
a prolongation of the R–R interval, with matched P–P and R–R intervals (184 ms) and a fixed PR interval once 
again (54 ms).
These observations suggested that in response to dobutamine the P wave rate and QRS rate both increased to 
similar degrees but were intermittently not identical, giving rise to the time shift of the P wave relative to the QRS 
complex. During such episodes, the QRS morphology continued to appear narrow and unchanged and identical 
to that earlier in the recording throughout the episode. This was consistent with a high escape focus, most likely 
junctional. However, the QRS complexes wherein the P wave is merged or absent could not be driven by sinus 
node impulse. Furthermore, where the QRS complex occurred in the absence of a sinus node input, there was no 
R–R delay; this makes it unlikely that this was a sinus pause with an accompanying isolated ventricular escape 
beat. In contrast, the consistent R - R interval during this period suggested that the ventricles were being driven 
by an ectopic focus.
The features above are thus consistent with intermittent isorhythmic AV dissociation with an accelerated 
junctional pacemaker rhythm, such as that reported previously. This could reflect some degree of age-related 
sinus node dysfunction that may have contributed with a delayed tachycardic response thus being usurped by the 
junctional focus35, 36.
Analysis of ECG features related to sino-atrial, atrio-ventricular and atrial conduction. Table 1 
summarises ECG features representing both activation and recovery events in each cardiac cycle in the atria and 
ventricles. This mean data was obtained from 5-min intervals both pre- and post-dobutamine challenge. Table 2 
shows the results of a multilevel linear regression analysis for independent and interactive associations between 
these ECG features with dobutamine challenge, increased age, and Scn5a+/ΔKPQ genotype.
Sino-atrial node (SAN) pacemaking increased in frequency following dobutamine challenge in all exper-
imental groups (Table 1). Thus, β-adrenergic stimulation had indistinguishable effects on ventricular rate in 
Scn5a+/ΔKPQ compared to WT. In both cases, this effect was diminished in old mice, consistent with a reduced 
chronotropic competence with age. Thus, ventricular rate, assessed from RR intervals and used as a measure 
for SAN function, increased following dobutamine challenge (p < 0.001). However, there were no independent 
effects of either age or genotype on ventricular rates whether before or following dobutamine challenge (Table 2). 
Nevertheless, age acted as a confounding factor (p = 0.08). Furthermore, age and dobutamine challenge together 
exerted interacting effects, resulting in old mice showing lower ventricular rates post-dobutamine challenge than 
young mice (p = 0.01). Finally, genotype exerted no interactive effects with either age or dobutamine challenge 
on ventricular rate
Dobutamine challenge, age and genotype exerted no independent or interactive effects upon atrial acti-
vation as reflected in recorded P wave durations. AV node conduction could be assessed from ECG PR seg-
ments intervening between the end of the P wave to the start of the QRS complex. AV node conduction was 
enhanced by dobutamine challenge, but compromised by age to extents indistinguishable between genotypes. 
Thus, dobutamine challenge independently decreased (p = 0.02), age independently increased (p = 0.001), but 
genotype exerted no independent effects on PR segments. There were no interactive associations observed for PR 
segments. Similar inferences emerged from the analysis of PR intervals, which reflect combined times required 
for atrial activation and AV conduction. Thus, dobutamine challenge independently decreased (p = 0.02), age 
Pre-dobutamine challenge Post-dobutamine challenge
WT Scn5a+/ΔKPQ WT Scn5a+/Δ;KPQ
Young Old Young Old Young Old Young Old
(7) (5) (7) (6) (7) (5) (7) (6)
Sino-atrial node function
 Ventricular rate (Hz) 6.7 ± 0.27 6.59 ± 0.14 6.53 ± 0.13 5.74 ± 0.28 10.17 ± 0.21 8.74 ± 0.19 10.25 ± 0.36 8.71 ± 0.36
Atrial conduction
 P wave duration (ms) 25.59 ± 0.49 25.64 ± 0.92 26.32 ± 0.42 27.26 ± 0.49 25.86 ± 0.40 25.79 ± 0.95 25.55 ± 0.19 28 ± 1.16
Atrio-ventricular node conduction
 PR segment (ms) 17.08 ± 2.50 23.95 ± 2.62 21.51 ± 2.19 23.23 ± 1.19 12.55 ± 1.60 22.61 ± 3.15 13.88 ± 3.76 20.74 ± 2.77
 PR interval (ms) 42.72 ± 2.36 49.61 ± 1.77 47.83 ± 1.95 50.59 ± 0.88 38.41 ± 1.87 48.39 ± 2.34 39.43 ± 3.89 48.74 ± 2.55
Ventricular activation
 QS duration (ms) 10.81 ± 0.47 10.51 ± 0.69 11.05 ± 0.39 13.44 ± 0.65 11 ± 0.48 10.33 ± 0.86 11.8 ± 0.58 13.01 ± 0.73
Ventricular recovery
 SC duration(ms) 30.64 ± 0.27 32.8 ± 1.10 32.39 ± 0.81 31.19 ± 0.55 29.65 ± 0.57 31.28 ± 0.70 31.64 ± 0.64 32.73 ± 1.16
 SD duration(ms) 41.37 ± 0.37 46.19 ± 3.48 55.41 ± 3.23 58.04 ± 2.82 41.32 ± 0.59 44.91 ± 3.42 49.74 ± 1.73 58.84 ± 3.55
 QC duration(ms) 41.45 ± 0.57 43.27 ± 1.41 43.44 ± 0.53 44.63 ± 0.84 40.65 ± 0.83 41.61 ± 1.35 43.45 ± 0.62 45.74 ± 0.89
 QD duration(ms) 52.18 ± 0.39 56.67 ± 3.46 66.46 ± 3.24 71.48 ± 3.03 52.32 ± 0.58 55.24 ± 3.10 61.55 ± 1.64 71.86 ± 3.54
Table 1. Electrocardiographic parameters.
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independently increased (p < 0.001), but genotype exerted no independent effects on PR intervals. There were no 
interacting effects involving any of the tested variables on such PR intervals.
Analysis of ECG features related to ventricular activation and recovery properties. ECG deflec-
tions related to the completion of activation and onset of recovery have previously been correlated with the S 
trough and the R’ peak. We adopted the QS duration to reflect overall ventricular activation in turn resulting from 
Na+ channel activation. Previous reports had suggested that including either the entire, or the late component 
of the R’ wave, partially captures ventricular repolarisation31, 37 overestimating the ventricular activation phase. 
This finding complements previous reports that had primarily associated LQTS3 only with prolonged repolari-
sation. Thus, dobutamine challenge, age and genotype exerted no independent effects on QS duration (Table 2). 
However, age and genotype interacted in increasing QS duration (p = 0.03) with no further interacting effects. 
Dobutamine challenge did not affect ventricular conduction in contrast to its effects of decreasing PR segment 
and PR interval, as well decreasing RR interval, in both Scn5a+/ΔKPQ and WT.
We studied the final electrocardiographic deflections ending each ECG complex as representing the overall 
duration of electrophysiological activity38. Two intervals following the QS deflection, SC and SD durations, were 
associated with ventricular recovery and were both analysed. The present findings suggest that SC duration may 
be an indication of the greater part of ventricular recovery towards the resting potential. However, the absence 
of changes in SC duration, even when comparing the LQTS3 model with WT, suggests that SC duration may not 
capture the prolonged QT interval attributable to the increased INa-L, normally associated with either murine 
Scn5a+/ΔKPQ hearts or LQTS3 patients. Thus, dobutamine challenge, age and genotype exerted no independ-
ent or interactive effects on SC duration. In contrast, Scn5a+/ΔKPQ mice showed longer SD durations than 
WT mice, under all circumstances. This identifies the SD duration with the LQTS3 phenotype and its associated 
recovery abnormality. This would in turn suggest that the SD duration is inclusive of INa-L contributions to the 
overall AP duration, typical of LQTS3 phenotypes. Thus, the predominant effect was that genotype independently 
increased SD duration (p < 0.001) but age had no independent effect. The effects of dobutamine challenge were 
suggestive of an independent borderline effect in decreasing the SD duration (p = 0.04). The latter is consistent 
with previous reports of the shortening of the QT interval for LQTS3 following β-adrenergic stimulation. This 
contrasts with the known effects of β-adrenergic stimulation in increasing QT interval in LQTS1 and LQTS239. 
Furthermore, dobutamine challenge, age, and genotype exerted no interactive effects on the SD duration.
The QC and QD durations provide indications of total ventricular excitation period including both activation 
and recovery. Both QC and QD durations were analysed due to the uncertainty in the murine model as to which 
exact ECG interval corresponds accurately to the human QT interval. The statistical analysis of both the QC and 
QD durations yielded similar associations, but for which there were higher significance values for QD duration. 
This would be explicable in terms of the QD duration encompassing more of the timecourse of INa-L than the QC 
duration. Thus, dobutamine challenge exerted no independent effects on QC and QD duration. However, age 
independently increased both QC and QD durations (p = 0.03 and p = 0.002 respectively). In addition, genotype 
independently increased both QC and QD durations (p = 0.001 and p < 0.001 respectively). There were no inter-
active effects on either QC or QD duration.
Thus, Scn5a+/ΔKPQ mice consistently showed longer QC and QD durations under all circumstances, con-
sistent with the clinical phenotype. However, in the case of QC duration, this difference was not attributable to 
changes in SC duration because all differences observed concerning SC duration were not significant. Therefore, 
the differences observed for QC durations were mainly attributable to differences in activation time, as reflected 
in QS duration, and not differences in recovery time, as reflected in SC duration. Thus, the results bearing on QS 
duration indicate interacting effects between age and genotype. This reflects the independent non-interacting 
effects of age and genotype upon the QC duration. Different inferences could be made from measurements of 
QD duration. Thus, the significant difference in QD duration appears to arise from (a) the significant effect of 
genotype on SD duration and (b) the interacting effects of age and genotype on QS duration.
Ventricular rate
P wave 
duration PR segment PR interval
QS 
duration SC duration SD duration QC duration QD duration
Treatment
Pre-dobutamine — — — — — — — — —
Post-dobutamine 3.6 (<0.001) x −4.3 (0.02) −4.2 (0.02) x x −1.7 (0.04) x x
Age
Young — — — — — — — — —
Old −0.48 (0.08) x 6.3 (0.001) 7.3 (<0.001) x x x 1.6 (0.03) 5.8 (0.002)
Genotype
WT — — — — — — — — —
Scn5a+/∆KPQ x x x x x x 12 (<0.001) 2.5 (0.001) 13 (<0.001)
Old × Scn5a+/∆KPQ x x x x 2.3 (0.03) x x x x
Old × post-dobutamine −1.0 (0.01) x x x x x x x x
Scn5a+/∆KPQ × post-
dobutamine x x x x x x x x x
Table 2. Results of multi-level linear regression of the association between various electrocardiographic 
features with dobutamine treat. Numbers are regression coefficients with the p-values in brackets, “x” indicates 
non-significance, “—” indicates a reference category.
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Histological analysis of fibrosis. We next sought correlations between the above electrocardiographic 
changes and the absence (Fig. 4a) or presence (Fig. 4b) of fibrotic change in the atria (i) and ventricles (ii) with 
similarly stratified groups of picrosirius red stained hearts (Fig. 4). Whereas gain of Na+ channel function would 
be expected to increase conduction velocity, fibrotic change may compromise conduction velocity40. This may 
arise through compromised gap junction function41 or fibroblast fusion to cardiac myocytes increasing their 
membrane capacitance42. However, the resulting effects on conduction velocity need not show simple correlations 
with these variables.
Histological assessments of the extent of fibrosis were carried out blindly by two investigators independently. 
Results were then compared for consistency by applying an intra-class correlation coefficient analysis (ICC). 
The ICC was 0.979 and 0.989 respectively for the atrial and ventricular fibrosis data, indicating a high level of 
consistency and permitting mean values for both atria (Fig. 5a) and ventricles (Fig. 5b) to be analysed. It was 
then possible to assess the extent to which the observed fibrotic change was sufficient to alter electrophysiological 
parameters.
Linear regression was performed to investigate the association between the level of fibrosis with age and geno-
type in the atria and ventricles. This used young and WT as reference categories. The analysis revealed significant 
Figure 4. Representative example of the absence of fibrotic change in young WT (a) and the presence of fibrotic 
change in an old Scn5a+/∆KPQ mouse (b) showing atrial (i) and ventricular (ii) sections.
Figure 5. Mean results for the fibrosis in the atria (a) and ventricles (b) Morphometric squares expressed as 
a percentage of all squares covering the tissues showing positive evidence of fibrotic changes as detected by 
picrosirius red staining in the different experimental groups. Numbers of hearts (n) shown below each bar. 
Linear regression with young and WT as reference categories revealed significant independent effects of (i) age 
in influencing ventricular (regression coefficient = 16, p < 0.001) but not atrial fibrosis and (ii) Scn5a+/∆KPQ vs 
WT genotypes on both atrial (regression coefficient = 19, p < 0.001) and ventricular (regression coefficient = 14, 
p < 0.001) fibrosis. There were no interacting effects arising from age and genotype.
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independent effects of (a) age in influencing ventricular (regression coefficient = 16, p < 0.001) but not atrial 
fibrosis and (b) Scn5a+/∆KPQ vs WT genotypes on both atrial (regression coefficient = 19, p < 0.001) and ven-
tricular (regression coefficient = 14, p < 0.001) fibrosis. There were no interacting effects arising from age and 
genotype. Thus, in atrial sections, the Scn5a+/ΔKPQ genotype but not age independently increased the level of 
fibrosis (p < 0.001) and there were no interactive effects between these factors. However, both this level of fibrosis 
and previous reports of reduced Nav1.5 expression with age in Scn5a+/ΔKPQ, appeared insufficient to modify 
P wave durations, in agreement with an earlier report9. Thus, it would appear that a lone association of Scn5a+/
ΔKPQ genotype with increased fibrosis does not suffice to alter P wave duration. For the ventricles, genotype 
and age independently increased the level of fibrosis (p < 0.001 for both) and there were no interactive effects. 
Thus, it could be deduced that the independent effects of Scn5a+/ΔKPQ genotype and old age on increasing the 
level of fibrotic change match the electrophysiological finding that age and genotype interact to produce reduced 
conduction in the ventricles, reflected in the prolonged QS duration.
Incidences of repolarisation alternans. Alternans in the ECG is defined as a presence of alternating 
changes in waveform amplitude43. Alternans reflects electrophysiological instabilities and clinically, repolarisa-
tion alternans, specifically T wave alternans, appears to predict clinical arrhythmic events with greater accuracy 
than other non-invasive markers, such as heart rate variability, signal averaged ECG, or reduced ejection fraction. 
It has also been implicated in the pathophysiological mechanism of sudden cardiac death (SCD)43. Ventricular 
repolarisation alternans is known to occur in LQTS44. However, previous reports have found conditions of adren-
ergic activity exerted paradoxical effects on the incidence of repolarisation alternans in LQTS345–47.
The present experiments compared incidences and durations of alternans episodes before and following 
dobutamine challenge, and any association of the resulting changes with age or genotype. This was accomplished 
by examining for changes in the amplitude of the largest ECG deflection reflecting ventricular repolarisation, 
Cpeak over fixed, 5 min, observation periods both before and following dobutamine challenge (Table 3). Thus, the 
absence (Fig. 6a) or presence (Fig. 6b) of alternans was assessed from the amplitudes of Cpeak wave in each con-
secutive ECG complex normalised to the corresponding amplitude of the Cpeak in the preceding ECG complex. If 
the values alternated between being >1 then <1 for a minimum of 12 consecutive beats, then this was counted as 
alternans. The duration of alternans was assessed from the number of beats over which this occurred. A multilevel 
negative binomial regression was used to assess association between numbers of incidences and of beats with 
(n)
Pre-dobutamine Challenge Post-dobutamine Challenge
Incidences Beats Incidences Beats
WT young (6) 3.7 ± 2.16 50.3 ± 28.35 0.5 ± 0.34 7.2 ± 4.62
WT old (5) 1.6 ± 1.17 22.0 ± 15.78 0.0 0.0
Scn5a+/KPQ young (7) 2.7 ± 2.07 35.3 ± 26.72 0.0 0.0
Scn5a+/KPQ old (6) 10.7 ± 5.60 160.7 ± 81.36 1.3 ± 0.99 22.3 ± 17.97
Table 3. Mean number of incidences and beats with Cpeak alternans pre-and post-dobutamine challenge.
Figure 6. Representative ECG traces to show the absence (a) and presence (b) of Cpeak alternans (a) This 
typical trace from a young WT animal shows normal sinus rhythm with the absence of Cpeak alternans, with the 
horizontal dotted line superimposed indicating that the level of the Cpeak remains consistent. (b) This typical 
trace from an old Scn5a+/∆KPQ animal shows normal sinus rhythm with the presence of Cpeak alternans, 
with the arrows indicating where Cpeak alternately increases its amplitude higher than the level of the other 
Cpeak deflections indicated by the horizontal dotted line. The dashed horizontal lines are to show that the QRS 
complex amplitude is remains consistent through the recording duration.
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Cpeak alternans with respect to dobutamine challenge, age and genotype. This used before dobutamine challenge, 
young and WT as reference categories respectively. The results showed an independent effect of dobutamine 
challenge decreasing the incidences of and number of beats with alternans (regression coefficients −2.7 and −3.9 
giving significances of p < 0.001 and 0.004 respectively), but no independent effects of age or genotype. However, 
age and Scn5a+/∆KPQ genotype had a significant interactive effect on increasing the incidences of and number 
of beats with alternans (regression coefficients 3.3 and 6.2 giving p = 0.02 and 0.02 respectively). There were no 
other significant interactive effects.
Thus, the present findings showed that age and genotype had an interactive association with a higher inci-
dence and number of beats with Cpeak alternans indicating the old Scn5a+/ΔKPQ mice show greater electro-
physiological instability. In addition, dobutamine challenge reduced the incidence of repolarisation alternans 
suggestive of anti-arrhythmic effects. This finding parallels clinical observations that LQTS3 does not share the 
clearcut pro-arrhythmic features following adrenergic stimulation in other LQTS.
Delays between increased ventricular rate and ventricular repolarisation change following 
dobutamine challenge. Previous reports have implicated cellular abnormalities with LQTS, which delay 
the QT interval shortening that normally follows an increased heart rate. This would result in an increased tran-
sient susceptibility to R-on-T related arrhythmias, where activation events are superimposed on a relatively 
delayed T wave of the preceding beat and this could degenerate into polymorphic VT48, 49. These delays are also 
likely to elude straightforward ECG detection. As with LQTS, the focus of ECG interpretation is generally on the 
prolongation of QT duration rather than the response of this QT duration to rate changes.
The present experiments accordingly explored for an absence (Fig. 7a) or presence (Fig. 7b) of such delayed 
changes in ventricular repolarisation duration following ventricular rate increases produced by dobutamine chal-
lenge (Table 4). The time lags between changes in QC and QD intervals and changes in ventricular rate were 
measured. A logistic regression model was then applied to the number of mice showing such a QC or a QD 
interval lag. Statistical testing was not applied to length of QC or QD interval lags due to the large number of 
mice showing no lag and the consequent large standard errors. The present analysis demonstrated an association 
between Scn5a+/ΔKPQ and the presence of both a QC and a QD interval lag (regression coefficients = 30 and 36; 
p = 0.02 and p = 0.004 respectively). Age was a confounding factor only for QC lag (regression coefficient = 8.9; 
p = 0.08), but this reflected one old WT outlier. Furthermore, as indicated above, it is QD interval that best 
reflects contributions from INa-L. These findings would therefore suggest that delays in changes in repolarisation 
duration in response to rate changes primarily result from effects of INa-L in turn largely dependent on genotype.
Figure 7. Representative examples showing the absence and presence of the lag in QC duration The dashed 
lines follow the gradient of the corresponding parts of the traces, with any intersection between two dashed lines 
indicating a change of gradient and hence an increase or decrease. These changes are marked by the vertical 
dotted lines. (a) These records represent the absence of a time lag between the ventricular rate increase (top 
trace) and the QC duration decrease (bottom trace) following dobutamine challenge exemplified in a young 
WT mouse. Thus, the vertical dotted line marks the same time point on each trace. (b) These records represent 
the presence of a time lag between the ventricular rate increase (top trace) and the QC duration decrease 
(bottom trace) following dobutamine challenge exemplified in an old Scn5a +/∆KPQ mouse. Thus, the vertical 
dotted lines mark different time points on each trace, with the horizontal arrow indicating this difference.
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Discussion
The present work extended previous explorations for electrophysiological phenotypes of LQTS3 using electro-
cardiographic (ECG) methods in intact genetically modified mice carrying the Nav1.5 gain-of-function Scn5a+/
ΔKPQ mutation. We extend findings from previous studies through (a) a detailed breakdown of ECG compo-
nents in terms of their underlying electrophysiological events to demonstrate novel potentially pro-arrhythmic 
changes in LQTS3. In particular, this revealed age-related changes related to conduction velocity, in addition 
to the alterations in recovery from excitation previously established in LQTS. (b) The present study demon-
strated an underlying age and genotype related fibrotic change for the first time for LQTS3. (c) Furthermore, 
this study suggested a basis for the paradoxical responses to β-adrenergic stimulation in which we correspond-
ingly demonstrate (d) an increase in the incidence of repolarisation alternans in old Scn5a+/ΔKPQ mice, which 
reduces with dobutamine challenge. This demonstrates anti-arrhythmic effects of β-adrenergic stimulation. This 
was accompanied by (e) slowed responses in ventricular repolarisation adaptation in Scn5a+/ΔKPQ mice in 
response to dobutamine challenge, which could highlight a potentially pro-arrhythmic effect during transient 
heart rate increases.
Firstly, episodes of ventricular electrophysiological activity in each ECG complex were separated into mul-
tiple activation and recovery components for the first time in the murine Scn5a+/ΔKPQ system. This extends 
previous analysis using only the single indicator of QT interval9, 28. Thus, activation changes were also demon-
strated, extending previous results that only examined recovery abnormalities in LQTS models. Two, QC and 
QD, parameters describing durations of ventricular electrophysiological activity were identified and analysed. 
Both parameters were prolonged independently both with the presence of Scn5a+/ΔKPQ genotype and age. 
Prolongations of the QC duration were attributed to increases in the activation, QS, component, in turn arising 
from interacting effects of age and Scn5a+/ΔKPQ genotype. However, neither age nor Scn5a+/ΔKPQ genotype 
affected the recovery, SC, component. The SC component is therefore unlikely to include any APD prolongation 
attributable to the increased INa-L known to occur in Scn5a+/ΔKPQ18.
In contrast, prolongation of the QD duration arose from changes in both activation, QS, and recovery, SD, 
components. Thus, SD was prolonged by the Scn5a+/ΔKPQ genotype but not by age. SD is therefore likely to 
include APD components specifically related to the increased INa-L in Scn5a+/ΔKPQ. A fuller breakdown of 
clinical ECG QT duration into activation and recovery components, than that currently adopted, could therefore 
reveal that prolonged QT intervals in LQTS reflect not only recovery, but also activation abnormalities.
This combination of both activation and recovery abnormalities observed in the old Scn5a+/ΔKPQ mouse 
might then account for an appearance of overlap syndromes with age in LQTS3 patients. These syndromes are 
characterised by a co-existence of more than one of the separate phenotypes expected from individual SCN5A 
mutations in the same patient50. SCN5A mutations are variously associated with LQTS3, BrS, progressive cardiac 
conduction defect (PCCD), sick sinus node syndrome (SSS), atrial fibrillation (AF), and even dilated cardiomy-
opathy (DCM)51. We thus complement previous reports in which an age-dependent penetrance of ECG char-
acteristics was associated with the SCN5A-1795insD mutation. The carriers of this particular mutation showed 
QT-prolongations and signs of conduction disease both of which were present from birth. They also showed BrS 
features that developed at a later age52, 53. The presence of overlap syndromes in ageing LQTS3 patients could have 
potential implications concerning the choice of therapeutic agents.
Secondly, the present experiments went on to explore for possible structural mechanisms for the observed 
age-dependent phenotypic changes. They complement the previous studies in murine loss-of-function Scn5a+/− 
hearts that had implicated fibrotic change in the arrhythmogenesis in BrS,40. The present study associated for 
the first time the gain-of-function Scn5a+/ΔKPQ mutation with increased fibrosis in both atria and ventri-
cles. The observed increases in fibrotic change likely arise from different signalling cascades from those in the 
loss-of-function BrS murine model, where Na+ channel deficiency manifests as a TGF-β1-mediated fibrosis asso-
ciated with Scn5a disruption or aging54. For example, the mechanism in the gain-of-function Scn5a+/ΔKPQ 
could relate to altered Ca2+ homeostasis accompanying the elevated INa-L55. The resulting Ca2+ load could then 
compromise mitochondrial function, increasing a pro-fibrotic ROS production56, 57.
Furthermore, the observed independent actions of both age and genotype upon ventricular fibrotic change 
correlated with the electrophysiological interacting effects of age and Scn5a+/ΔKPQ genotype in compromis-
ing ventricular activation. The mechanistic basis for this could potentially involve gap junction disruption from 
the fibrotic change, which would then increase resistance to local circuit currents and hinder AP propagation41. 
Alternatively, fibroblasts or myofibroblasts (Mfbs) could form couplings with cardiomyocytes through Cx43 and 
Cx45 binding58, 59. The resulting increased cell capacitance would reduce conduction velocity to extents varying 
with ratio of the numbers of Mfbs to cardiomyocytes42, 60, 61. This would increase arrhythmic tendency through 
formation of slow-conducting re-entry circuits62, 63. Thus, therapeutic agents for LQTS3 patients, particularly with 
(n)
QC interval lag QD interval lag
Number Length (ms) Number Length (ms)
WT young (7) 0 0.0 0 0.0
WT old (5) 1 8.0 1 13.0
Scn5a+/KPQ young (7) 3 26.4 ± 20.84 6 47.1 ± 21.38
Scn5a+/KPQ old (6) 5 50.8 ± 21.54 4 101.7 ± 39.36
Table 4. Number of mice with a time lag between their ventricular rate increase and ventricular repolarisation 
shortening following dobutamine challenge and the mean length.
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age, may need to addresses the ventricular activation deficit. One possibility may be through targeting the fibrotic 
change itself. For example, the use of angiotensin-converting enzyme inhibitors to inhibit RAAS have been shown 
to reduce myocardial fibrosis in both experimental and clinical studies64, 65.
Thirdly, ECG measurements were compared before and following acute β-adrenergic challenge. Thus 
dobutamine challenge exerted positive chronotropic and dromotropic effects, reflected in increased ventricular 
rates and reduced PR segment and PR interval durations, whilst leaving QS intervals unchanged. This could 
reflect similar and positive effects of β-adrenergic stimulation upon both pacing currents and atrial but not ven-
tricular conduction in both WT and Scn5a+/ΔKPQ.
Fourthly, ventricular repolarisation alternans was compared between experimental groups, and the effect 
of dobutamine challenge upon this then investigated in the study population. Before pharmacological inter-
vention, old Scn5a+/ΔKPQ mice showed higher incidences and durations of ventricular repolarisation alter-
nans. Clinically, ventricular repolarisation alternans, reflected in T-wave alternans (TWA), is known to occur in 
LQTS44, with implications for the pathophysiological mechanism of sudden cardiac death (SCD)43. Repolarisation 
alternans is closely related to the Ca2+ cycling and mechanical alternans43 attributed to variations in intracellular 
sarcoplasmic reticulum (SR) Ca2+ release66. Thus, both are abolished by reduced [Ca2+]o or ryanodine-mediated 
RyR2 block44. An increased INa-L attributed to Scn5a+/ΔKPQ would increase [Ca2+]i through the power function 
relationship it bears to [Na+]i67, 68 thereby contributing to development of alternans. The observed interacting 
effects of Scn5a+/ΔKPQ genotype and age are consistent with increased incidences of alternans in old Scn5a+/
ΔKPQ mice producing an underlying Ca2+ cycling alternans given age-related reductions in myocardial SR Ca2+ 
ATPase (SERCA) density69.
Dobutamine challenge then exerted anti-arrhythmic effects in reducing the incidence and duration of repo-
larisation alternans. Clinical findings however indicate that adrenergic activity and heart rate exert paradoxical 
effects on the incidence of TWA in LQTS3. This is reflected in earlier findings of nocturnal episodes of peak TWA 
in LQTS3 patients that were associated with conditions of rate suppression45, 46. Studies separating the effects of 
β-adrenergic stimulation and imposed heart rates implicated the increases in heart rate rather than β-adrenergic 
stimulation in TWA47. The present finding that β-adrenergic stimulation paradoxically reduces repolarisa-
tion alternans in LQTS3 might reflect reduction of the normal phospholamban (PLB)-mediated inhibition of 
SERCA-mediated Ca2+ re-uptake70, 71. Alternatively, β-adrenergic stimulation has been reported to shift the INa 
inactivation–voltage relationship to more negative potentials decreasing window current and hence INa-L72–75. This 
would decrease [Na+]i, and in turn [Ca2+]i thereby possibly reducing repolarisation alternans.
Finally, the experiments demonstrated that with the Scn5a+/ΔKPQ genotype, there was a delay in the onset 
time over which ventricular repolarisation duration changed following corresponding increases in ventricular 
rate produced by dobutamine challenge. In response to a change in ventricular rate, the QT interval normally 
shortens immediately and then follows a more gradual mono-exponential reduction to a new steady-state value76. 
Thus, a discrepancy in the onset time of this shortening could result in a transient increase in ventricular repo-
larisation time relative to RR interval. This may confer arrhythmic susceptibility during heart rate increases in 
LQTS3 patients for example48. The present findings thus complement previous reports that had similarly reported 
paradoxically increased AP duration in mice modelling LQTS3 following sudden rate increases18. The previous 
studies were performed in isolated ventricular preparations under artificial pacing rather than employing intact 
animals with normal sympathetic innervations and β-adrenergic stimuli replicating the in vivo situation.
Conclusions
The present study demonstrates for the first time that a gain-of-function Scn5a+/ΔKPQ mutation is associated 
with an increased level of fibrotic change. This increased fibrosis associated with Scn5a+/ΔKPQ and age slows 
conduction in the ventricles and could be the cause of the prolonged activation, QS, interval in old Scn5a+/
ΔKPQ mice. This has clinical implications in that arrhythmic events in elderly LQTS patients may be due to an 
activation abnormality as opposed to a sole recovery abnormality. Thus, therapeutic options for LQTS patients 
may need to be expanded from solely treating the prolonged ventricular repolarisation to treating any activation 
deficits arising from fibrotic change. Furthermore, therapeutic β-adrenergic agonists or antagonists for LQTS3 
patients specifically should consider the paradoxical effects of such administration. The present study demon-
strates both pro- and anti-arrhythmic effects of dobutamine challenge, recapitulating the clinical observations of 
its paradoxical effects. However, the present results suggest that LQTS3 patients are likely to be pro-arrhythmic 
during the change of heart rate following β-adrenergic stimulation. Moreover, the present results suggest that 
the anti-arrhythmic effects of β-adrenergic stimulation may be more apparent with age, as there is a reduction in 
repolarisation alternans and improvement in conduction following acute dobutamine administration. This indi-
cates that age-specific drug choice may be required as the disease phenotype can change with age.
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